Learn about the latest treatments for metastatic uterine cancer. We’ve got it covered, from new FDA approvals to emerging approaches in targeted therapy, CAR T-cell therapy, other immunotherapies, drug combinations, and more.

  •   George Lundberg, MD

    The most common brain tumors are other types of cancer that have spread (or “metastasized”) to the brain from a primary site elsewhere in the body. And, the genomic makeup of the brain metastases may not be the same as the primary cancer. An article from The ASCO Post discusses what this means for treatment.

    .

  •  

    How an Emory Professor would Treat Her Own Advanced Endometrial Cancer

    With: Jane Meisel, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Jane Meisel, MD, how she would handle her own advanced endometrial cancer. Dr. Meisel is Associate Professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University in Atlanta, GA. Curious Dr. George: Please consider a hypothetical… Read more »

  • SEE ALL
Precision oncology is very complicated and changes every day. The scientists of Cancer Commons provide rapid, compassionate, scientifically sound information about best options, a remarkable free service.

Razelle Kurzrock, MD
U.C. San Diego, CureMatch, Inc.

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in molecular testing that could help guide uterine cancer treatment, such as detection of genetic mutations and other biomarkers.

Some of the most promising new treatments for metastatic uterine cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

  •   George Lundberg, MD

    Press release from Ohio State University Wexner Medical Center curated by Contributing Editor George Lundberg, MD.

    This press release outlines promising preliminary results from two phase 2 clinical trials testing the drug balstilimab alone or in combination with zalifrelimab.

    .

  •   George Lundberg, MD

    Research paper from the Journal of Clinical Oncology, selected by Editor in Chief George Lundberg, MD, who notes:

    CAR T-cell therapy has been approved by the U.S. Food and Drug Administration (FDA) for certain hematologic malignancies. This early study demonstrates its effectiveness in human papillomavirus (HPV)-induced metastatic cervical cancer as well.

    Go to full article published by the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • SEE ALL
In a field as complex and dynamic as molecular oncology in 2020, Cancer Commons offers an amazing opportunity for patients with advanced cancer to obtain scientifically up-to-date additional options that may improve both the length and quality of their lives, all free of charge.

Gavin Gordon, PhD
Molecular Pathologist

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

  •  

    Pediatric Palliative Care: A Specialty Comes of Age

    Sarah Friebert, MD

    For a child with cancer, palliative care can provide much-needed relief from stress and symptoms—for the patient and their family alike. Palliative care is given alongside cancer treatment, and is not synonymous with “end-of-life” care. In fact, anyone with a serious illness can benefit from palliative care, no matter their long-term outlook. Because of its importance for children with cancer, we are honored to… Read more »

  •   Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Pancreatic cancer patients share their experiences with pre-chemo anxiety and their personal strategies for overcoming it.

    .

  •   George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • SEE ALL

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

More patient stories

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

  •  

    A Powerful Knowledge Base for Precision Oncology

    With: Hongxin Zhang

    Genetic mutations found in a tumor can be important clues to the patient’s best treatment options. Memorial Sloan Kettering Cancer Center (MSK) in New York has developed a product called OncoKB™, which enables anyone to access and navigate key clinical information about the various genetic abnormalities that may be found in tumors. Here, Curious Dr. George asks MSK Lead Software Engineer Hongxin Zhang about… Read more »

  •  

    Harnessing Each Patient’s Data to Help Many More

    With: Kaumudi Bhawe, PhD

    At Cancer Commons, we don’t just help people navigate cancer treatment; we learn from everyone we help. Here, our Curious Dr. George asks Cancer Commons Clinical Scientist Kaumudi Bhawe, PhD, to share how new knowledge can be captured from every patient to help many more. Curious Dr. George: Cancer Commons has accumulated in-depth data on many hundreds of patients with various cancers. Because of the… Read more »

  • SEE ALL

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.